Placement of High Dose Neurotoxins for Treatment-Resistant Rosacea
rosaceaRosacea is a chronic inflammatory skin condition characterized by facial flushing, erythema, telangiectasias, and papulopustular lesions. Treatment for rosacea includes limiting inciting factors and reducing inflammation with topical and oral therapies. Traditional therapies primarily focus on the papulopustular or background erythematotelangiectatic component of rosacea, leaving symptoms of flush …
rosacea
Leukemia Cutis in Skin of Color
leukemia cutisThe various presentations of many dermatologic conditions among various skin types are slowly being elucidated throughout the recent years. These differences present as an issue as it leads to delayed diagnosis, treatment, and poorer quality of life. Herein, JDD authors  Susuana Adjei MD, et al.  present the characteristics of leukemia cutis in a skin of color patient with diagnosed chronic myel …
leukemia cutis
Self-Reported Long-Term Side Effects of Isotretinoin: A Case Series
isotretinoin In this brief communication, JDD authors T. Roxana Ghadimi BS, Michael J. Martinez BS, and Evan A. Rieder MD present self-reported long-term, remote side effects to isotretinoin that dermatologists must be aware of. INTRODUCTION Isotretinoin is considered the gold standard treatment for severe nodulocystic acne, though it has been the subject of controversy in the media for concerns relate …
isotretinoin
Rituximab-Induced Alopecia Universalis in a Patient With Bullous Pemphigoid
Alopecia areata is a CD8+ T-lymphocyte driven autoimmune disorder leading to reversible hair loss. While most commonly presenting as isolated well-demarcated non-cicatricial alopecic patches on the scalp, subtypes of alopecia areata include alopecia totalis with loss of all scalp hair and alopecia universalis with complete loss of all body hair. Although primarily an idiopathic condition, several …
Dermal Hypersensitivity Reaction to Semaglutide: Two Case Reports
Semaglutide is a glucagon-like peptide-1 (GLP-1) analog that was FDA-approved in 2017 for treatment of type II diabetes and in 2021 for treatment for chronic weight management in adults with obesity or overweight with at least one weight-related condition.1 Due to its longer duration of action, it is typically administered subcutaneously once weekly. The safety profile of semaglutide is similar to …